Demographic, clinicoserological, and virological features of 170 patients with mixed cryoglobulinaemia
| *At presumed disease onset; †invariably membranoproliferative glomerulonephritis. | |
| HbsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus. | |
| Mean (SD; range) age (years)* | 51 (11; 29–73) |
| Female/male ratio | 2.8 |
| Mean (SD; range) disease duration (years) | 11.9 (6.4; 1–34) |
| Purpura | 91% |
| Weakness | 89% |
| Arthralgias | 83% |
| Arthritis (non-erosive) | 10% |
| Raynaud's phenomenon | 34% |
| Sicca syndrome | 36% |
| Peripheral neuropathy | 36% |
| Renal involvement† | 31% |
| Liver involvement | 70% |
| B cell non-Hodgkin's lymphoma | 7.5% |
| Hepatocellular carcinoma | 2.4% |
| Mean (SD) cryocrit (%) | 3.7 (7.0) |
| Type II/type III mixed cryoglobulins | 2/1 |
| Mean (SD) CH50 (units; normal, 160–220) | 83 (58) |
| Mean (SD) C3 (mg/l; normal, 600–1300) | 770 (280) |
| Mean (SD) C4 (mg/l; normal, 200–550) | 100 (150) |
| Antinuclear antibodies | 24% |
| Antimitochondrial antibodies | 10% |
| Antismooth muscle antibodies | 23% |
| Anti-extractable nuclear antigen antibodies | 7% |
| Anti-HCV antibodies | 90% |
| HCV RNA | 86% |
| Anti-HBV antibodies | 40% |
| HBsAg | 3.5% |